Treats infections caused by susceptible strains of the designated microorganisms in the…. ANDA 75928, held by Rubicon Research. Ciprofloxacin Hydrochloride.
As of Nov 21, 2026, ANDA 75928 (Ciprofloxacin Hydrochloride), held by Rubicon Research, was first approved by FDA on Jun 9, 2004, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE: Ciprofloxacin ophthalmic Solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Corneal Ulcers: Pseudomonas aeruginosa Serratia marcescens * Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus (Viridans Group) * Conjunctivitis: Haemophilus influenzae Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae *Efficacy for this organism was studied in fewer than 10 infections.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 9, 2004 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ciprofloxacin HydrochlorideEQ 0.3% BASE · solution/drops;ophthalmic | Ciprofloxacin Hydrochloride | Rx |
| May 25, 2011 | Supplement 15Manufacturing | Approved | None posted |
| Apr 22, 2005 | Supplement 6Labeling | Approved | None posted |
| Jun 9, 2004 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters